A detailed history of Northern Trust Corp transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 276,660 shares of PHAT stock, worth $4.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
276,660
Previous 283,200 2.31%
Holding current value
$4.85 Million
Previous $3.01 Million 5.25%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$8.97 - $12.05 $58,663 - $78,807
-6,540 Reduced 2.31%
276,660 $2.85 Million
Q1 2024

May 14, 2024

SELL
$6.21 - $11.05 $41,103 - $73,139
-6,619 Reduced 2.28%
283,200 $3.01 Million
Q4 2023

Feb 13, 2024

BUY
$6.99 - $10.71 $147,090 - $225,370
21,043 Added 7.83%
289,819 $2.65 Million
Q3 2023

Nov 13, 2023

BUY
$10.26 - $15.7 $529,313 - $809,963
51,590 Added 23.75%
268,776 $2.79 Million
Q2 2023

Aug 11, 2023

BUY
$7.28 - $14.32 $31,194 - $61,361
4,285 Added 2.01%
217,186 $3.11 Million
Q1 2023

May 15, 2023

BUY
$6.19 - $12.36 $11,463 - $22,890
1,852 Added 0.88%
212,901 $1.52 Million
Q4 2022

Feb 13, 2023

BUY
$9.18 - $11.53 $177,541 - $222,990
19,340 Added 10.09%
211,049 $2.37 Million
Q3 2022

Nov 14, 2022

BUY
$6.46 - $12.11 $11,763 - $22,052
1,821 Added 0.96%
191,709 $2.12 Million
Q2 2022

Aug 12, 2022

BUY
$6.2 - $15.5 $68,683 - $171,709
11,078 Added 6.2%
189,888 $1.6 Million
Q1 2022

May 13, 2022

SELL
$11.55 - $20.06 $105,047 - $182,445
-9,095 Reduced 4.84%
178,810 $2.43 Million
Q4 2021

Feb 08, 2022

BUY
$17.83 - $33.15 $32,611 - $60,631
1,829 Added 0.98%
187,905 $3.7 Million
Q3 2021

Nov 15, 2021

SELL
$30.69 - $36.83 $270,072 - $324,104
-8,800 Reduced 4.52%
186,076 $5.97 Million
Q2 2021

Aug 13, 2021

BUY
$32.66 - $39.87 $2.06 Million - $2.51 Million
63,020 Added 47.79%
194,876 $6.6 Million
Q1 2021

May 12, 2021

BUY
$33.86 - $48.68 $18,115 - $26,043
535 Added 0.41%
131,856 $4.95 Million
Q4 2020

Feb 11, 2021

SELL
$33.22 - $50.26 $37,438 - $56,643
-1,127 Reduced 0.85%
131,321 $4.36 Million
Q3 2020

Nov 16, 2020

SELL
$29.24 - $40.19 $321,786 - $442,290
-11,005 Reduced 7.67%
132,448 $4.86 Million
Q2 2020

Aug 14, 2020

BUY
$25.06 - $54.6 $305,606 - $665,847
12,195 Added 9.29%
143,453 $4.72 Million
Q1 2020

May 14, 2020

BUY
$24.65 - $42.83 $414,908 - $720,914
16,832 Added 14.71%
131,258 $3.39 Million
Q4 2019

Feb 14, 2020

BUY
$18.59 - $37.67 $2.13 Million - $4.31 Million
114,426 New
114,426 $3.56 Million

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $686M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.